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Abstract
The 3α,5α- and 3α,5β-reduced derivatives of progesterone, deoxycorticosterone,
dehydroepiandrosterone and testosterone enhance GABAergic neurotransmission and produce
inhibitory neurobehavioral and anti-inflammatory effects. Despite substantial information on the
progesterone derivative (3α,5α)-3-hydroxypregnan-20-one (3α,5α-THP, allopregnanolone), the
physiological significance of the other endogenous GABAergic neuroactive steroids has remained
elusive. Here, we describe the validation of a method using gas chromatography-mass spectrometry
to simultaneously identify serum levels of the eight 3α,5α- and 3α,5β-reduced derivatives of
progesterone, deoxycorticosterone, dehydroepiandrosterone and testosterone. The method shows
specificity, sensitivity and enhanced throughput compared to other methods already available for
neuroactive steroid quantification. Administration of pregnenolone to rats and progesterone to
women produced selective effects on the 3α,5α- and 3α,5β-reduced neuroactive steroids, indicating
differential regulation of their biosynthetic pathways. Pregnenolone administration increased serum
levels of 3α,5α-THP (+1488%, p<0.001), (3α,5α)-3,21-dihydroxypregnan-20-one (3α,5α-THDOC,
+205%, p<0.01), (3α,5α)-3-hydroxyandrostan-17-one (3α,5α-A, +216%, p<0.001), (3α,5α,17β)-
androstane-3,17-diol (3α,5α-A-diol, +190%, p<0.01). (3α,5β)-3-hydroxypregnan-20-one (3α,5β-
THP) and (3α,5β)-3-hydroxyandrostan-17-one (3α,5β-A) were not altered, while (3α,5β)-3,21-
dihydroxypregnan-20-one (3α,5β-THDOC) and (3α,5β,17β)-androstane-3,17-diol (3α,5β-A-diol)
were increased from undetectable levels to 271 ± 100 and 2.4 ± 0.9 pg ± SEM, respectively (5/8 rats).
Progesterone administration increased serum levels of 3α,5α-THP (+1806%, p<0.0001), 3α,5β-THP
(+575%, p<0.001), 3α,5α-THDOC (+309%, p<0.001). 3α,5β-THDOC levels were increased by
307%, although this increase was not significant because this steroid was detected only in 3/16 control
subjects. Levels of 3α,5α-A, 3α,5β-A and pregnenolone were not altered. This method can be used
Corresponding Author: A. Leslie Morrow, Ph.D., University of North Carolina School of Medicine, 3027 Thurston-Bowles Building,
CB#7178, Chapel Hill, NC, 27599-7178, USA, Tel.: +1-919-9667682, Fax: +1-919-9669099, morrow@med.unc.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Steroids. Author manuscript; available in PMC 2010 April 1.
Published in final edited form as:













to investigate the physiological and pathological role of neuroactive steroids and to develop
biomarkers and new therapeutics for neurological and psychiatric disorders.
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1. Introduction
Neuroactive steroids are endogenous neuromodulators, synthesized de novo in the brain as
well as in the adrenals and gonads. They have potent effects on neurotransmission mediated
by γ-aminobutyric acid type A (GABAA) receptors[1] on which they act through specific
binding sites on the α subunits[2]. The 3α,5α- and 3α,5β-reduced metabolites of progesterone,
deoxycorticosterone, dehydroepiandrosterone (DHEA) and testosterone[3-5] induce potent
GABAergic actions that result in anxiolytic, anticonvulsant, sedative/hypnotic, cognitive and
pro-copulatory effects[6,7].
GABAergic neuroactive steroids play a crucial role in physiological states like stress[8],
pregnancy[9], ovarian cycling[10,11], puberty[12,13] and aging[14]. Their concentrations are
increased by administration of various psychoactive drugs, including ethanol[15,16], nicotine
[17], caffeine[18], tetrahydrocannabinol[19], morphine[19,20], antidepressants[21-23] and the
atypical antipsychotics clozapine and olanzapine[24-27]. GABAergic neuroactive steroid
levels are altered in several mood and emotional disorders, including anxiety, depression,
premenstrual dysphoric disorder, schizophrenia, epilepsy and drug addiction[5,16,22,28,29].
Furthermore, neuroactive steroids possess neuroprotective and neurotrophic effects[30-32] and
their levels are altered in neurodegenerative diseases[33].
Recent evidence suggests a therapeutic potential for neuroactive steroids in traumatic brain
injury[34,35], multiple sclerosis[36,37], epilepsy[38], Niemann-Pick type C disease[30],
schizophrenia[29,39,40], depression[21,22], and alcoholism[16]. In fact, clinical trials using
the precursors pregnenolone and progesterone or the synthetic neuroactive steroid ganaxolone
are under investigation for traumatic brain injury[35], multiple sclerosis[36,37], schizophrenia
[41,42], and epilepsy[38] (see also Morrow, 2007[7] for review). It is postulated that the
therapeutic effects of progesterone for traumatic brain injury[43] and pregnenolone for
schizophrenia[41] are due, in part, to their conversion into the potent GABAergic neuroactive
steroid (3α,5α)-3-hydroxypregnan-20-one (3α,5α-THP). Indeed, pregnenolone is metabolized
into several steroid hormones and their 3α,5α- and 3α,5β-reduced metabolites also possess
GABAergic properties. Since progesterone, deoxycorticosterone, DHEA and testosterone are
present at high concentrations in blood, the 3α,5α- and 3α,5β-reduced GABAergic metabolites
of these steroids are likely to play important physiologic roles.
In most of the aforementioned studies, neuroactive steroid levels were measured using a
radioimmunoassay. Radioimmunoassays can provide highly sensitive measurements of
neuroactive steroids in the brain, especially after extensive clean-up or purification by HPLC.
However, in serum samples neuroactive steroids are present at much lower concentrations.
Furthermore, the lack of specific antibodies does not allow the simultaneous measurement of
multiple neuroactive steroids. In addition, antibodies currently available do not always
discriminate among the different isomers of the same compound and this limitation appears to
be particularly important in the case of human studies. Humans synthesize both 3α,5α- and
3α,5β-reduced neuroactive steroids[22,44-47]. Considering the abundance of precursors and
the common metabolic enzymes, it is likely that the GABAergic metabolites of progesterone,
deoxycorticosterone, DHEA and testosterone are both singularly and coordinately significant
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physiological regulators of central nervous system excitability (see special issue on neuroactive
steroids[7]).
Studies using gas chromatography and mass spectrometry (GC-MS) detection of neuroactive
steroids have appeared, but are restricted to a few of the GABAergic steroids[21,22,29,
47-51] (see also Purdy et al.[52] for review). GC-MS allows the simultaneous detection of low
amounts of neuroactive steroids in brain, cerebrospinal fluid or serum samples. Here we
describe the validation of a GC-MS method following solid phase purification to
simultaneously quantify serum levels of eight GABAergic neuroactive steroids: 3α,5α-THP,
(3α,5β)-3-hydroxypregnan-20-one (3α,5β-THP), (3α,5α)-3,21-dihydroxypregnan-20-one (3α,
5α-THDOC), (3α,5β)-3,21-dihydroxypregnan-20-one (3α,5β-THDOC), (3α,5α)-3-
hydroxyandrostan-17-one (3α,5α-A), (3α,5β)-3-hydroxyandrostan-17-one (3α,5β-A), (3α,5α,
17β)-androstane-3,17-diol (3α,5α-A-diol), (3α,5β,17β)-androstane-3,17-diol (3α,5β-A-diol)
and their precursor pregnenolone. The biosynthetic pathway is shown in Figure 1. This method
has several distinct advantages over prior procedures that require labor intensive HPLC
purification, relatively large sample volumes of 1 ml, and quantify fewer neuroactive steroids
(see Purdy et al.[52] for review). With this comprehensive method, we investigated the effects
of pregnenolone administration to rats and progesterone administration to women on serum
levels of these neuroactive steroids.
2. Materials and Methods
2.1. Materials/Chemicals
Steroid standards (>99% purity) for 3α,5α-A, 3α,5β-A, 3α,5α-A-diol, 3α,5β-A-diol, 3α,5β-
THP, 3α,5β-THDOC and pregnenolone were purchased from Steraloids, Inc. (Newport, RI,
USA). Deuterium-labeled standards (>95% purity) for (d4-17,21,21,21)-3α,5α-THP and
(d3-17,21,21)-3α,5α-THDOC were purchased from Cambridge Isotope Laboratories, Inc.
(Andover, MA, USA). (d4-2,2,4,4)-3α,5α-A was purchased from Cerilliant (Round Rock, TX,
USA). 3α,5α-THP, 3α,5α-THDOC and (d4-17,21,21,21)-pregnenolone (98% purity) were
synthesized by Dr. R.H. Purdy (Veterans Medical Research Foundation, San Diego, CA, USA).
Derivatization reagent heptafluorobutyric acid anhydride was purchased from Pierce
(Rockford, IL, USA). Monodeuterated ethanol was from Sigma-Aldrich (St. Louis, MO, USA).
Organic solvents were pesticide grade from Thermo Fisher Scientific, Inc. (Waltham, MA,
USA).
2.2. Steroid extraction and separation
Neuroactive steroids were purified from serum by solid phase extraction as described by
Budzinski et al.[53], with some modifications. Serum samples (300 μl) were spiked with 400
pg/ml of each deuterated internal standard and applied to C18 solid phase extraction columns
(RPN1910, 500 mg, GE Healthcare, UK) that had been preconditioned with 4 ml methanol
and 4 ml distilled water. The column containing the sample was washed with 4 ml distilled
water in order to remove high polar impurities. Columns were dried under vacuum for 30
minutes and neuroactive steroids were then eluted with 2 ml methanol. The extracts were
evaporated in a speed vacuum concentrator (Thermo Fisher Scientific, Inc., Waltham, MA,
USA). The dry residue was resuspended in 2 ml of ethyl acetate/methanol (80/20, v/v) and the
sample was filtered through a NH2 column (Supelclean LC-NH2, 500 mg, Supelco, Bellefonte,
PA, USA) previously preconditioned with 4 ml of ethyl acetate and 4 ml of ethyl acetate/
methanol (80/20, v/v). The neuroactive steroids passed unretained through the sorbent, and the
eluate was collected. The NH2 column was further rinsed with 2 ml more of the solvent mixture
and the combined eluates were evaporated in the speed vacuum concentrator before
derivatization. Purification with the NH2 column was necessary to improve the validation and
accuracy of the assay. We found that % accuracy for 3α,5α-THP, 3α,5β-THP, 3α,5α-THDOC
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and 3α,5β-THDOC was 72 ± 10.8, 115 ± 21.0, 129 ± 13.2 and 128 ± 14.7, respectively, after
C18 column purification alone, vs. 88 ± 4.6, 101 ± 6.1, 102 ± 2.7 and 106 ± 4.6, respectively,
after the combination of C18 plus NH2 column purification.
2.3. Preparation of calibration curves
Neuroactive steroid standards were dissolved in reagent grade alcohol (Thermo Fisher
Scientific, Inc., Waltham, MA, USA) to obtain 10 mg/ml stocks. Stocks were made fresh every
month and were diluted the day of the experiment to obtain 2, 10, 20, 50, 100, 200, 500, 1000,
2000 and 3000 pg/ml concentrations for each steroid. Calibration curves were made in 300
μl distilled water spiked with 5 μl human charcoal-stripped serum (Gemini Bio-Products,
Woodland, CA, USA), with 400 pg/ml of each deuterated internal standard and with the
appropriate known concentration of neuroactive steroids. This concentration of human
charcoal-stripped serum was chosen since undiluted serum contained 10-40 pg/ml of six of the
eight neuroactive steroids that could alter the accuracy of the assay for low concentrations of
steroids. A blank standard (5 μl human charcoal-stripped serum in 300 μl distilled water) was
also included. Calibration curves underwent the same extraction procedure as the samples.
2.4. Derivatization
Samples were derivatized according to Uzunova et al.[22] and Marx et al.,[29]. Dried samples
after purification were resuspended in 600 μl methanol and transferred to derivatization vials
(Wheaton, Millville, NJ, USA). Methanol was evaporated and samples were resuspended in
450 μl of ethyl acetate and 50 μl of heptafluorobutyric acid anhydride, followed by vortex
mixing. Samples were allowed to react for two hours at room temperature and were dried under
a gentle stream of nitrogen. Derivatized samples were resuspended in 10 μl of heptane and 2
μl of each sample was injected in duplicate into the GC-MS.
2.5. GC-MS analysis
Analysis was carried out on an Agilent 6890 gas chromatograph coupled to a 5973 mass
selective detector (Agilent Technologies, Inc., Santa Clara, CA, USA) operated in negative
chemical ionization mode. A capillary column (30 m × 0.25 mm, 0.25 μm film thickness, 5%-
phenyl-methylpolysiloxane, J&W Scientific, Agilent Technologies, Inc., Santa Clara, CA,
USA) was used to separate the derivatives of each neuroactive steroid. Samples (2 μl) were
injected into the GC in splitless mode at 12 psi and at 250°C using a 7683 series injector (Agilent
Technologies, Inc., Santa Clara, CA, USA). The carrier gas was ultrapure helium (99.9995%,
National Welders, Durham, NC, USA) set at constant flow of 1.0 ml/min. Methane (99.999%
National Welders, Durham, NC, USA) was the reagent gas. The initial GC oven temperature
was 75°C (0.86 min hold), followed by an increase to 210°C at 35° increments (3 min hold),
an increase to 235°C at 2.5° increments (9 min hold) and finally to 310°C at 25° increments
(2 min hold). The transfer line temperature was maintained at 280°C. Neuroactive steroids
were analyzed by single ion monitoring. The data acquisition was broken into retention
windows corresponding to the elution of the different neuroactive steroid groups (Table 1).
The temperatures of mass spectrometer source and quadrupole were 150°C.
2.6. Biological application of the method
Male Sprague-Dawley rats (200-250 g) were purchased from Harlan (Indianapolis, IN, USA).
After arrival at the animal facility, rats were allowed to acclimate for one week. They were
housed four per cage under 12h light, 12h dark cycle (light on from 0700 to 1900 h) and at a
constant temperature of 22 ± 2°C and relative humidity of 65%. They had free access to water
and standard laboratory food at all times. Rats were habituated to handling and intraperitoneal
(i.p.) injection every day for five days before the experiment. Pregnenolone, 50 mg/kg, was
dissolved in 45% β-cyclodextrine and was administered i.p. 60 minutes before sacrifice. This
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interval was chosen to allow time for conversion of pregnenolone to its GABAergic
metabolites. The blood was collected from the trunk into red cap Vacutainer tubes, immediately
after decapitation. It was centrifuged (3000 rpm for 15 min at 4°C) and serum samples were
stored in plastic minivials at -80°C until use. Adequate measures were taken to minimize pain
or discomfort of the animals. Animal care and handling throughout the experimental
procedures were in accordance with National Institutes of Health Guidelines under Institutional
Animal Care and Use Committee approved protocols.
Human blood samples were obtained from healthy women volunteers as previously described
[54]. Each woman was tested during days 2-6 of the follicular phase of menstrual cycle, when
endogenous levels of progesterone are low[55-57]. Blood samples for baseline were taken 15
minutes before and 160 minutes after oral administration of 300 mg of micronized
progesterone. Neuroactive steroid determination was conducted in serum. The study was
conducted in compliance with the Declaration of Helsinki
(http://www.wma.net/e/policy/b3.htm) and was approved by the University of North Carolina
at Chapel Hill, Committee on Protection of the Rights of Human Subjects. Informed consent
was obtained from participants after the study was fully explained.
2.7. Statistical analysis
Linear regression curves, Pearson's correlations and statistical analysis were performed using
a commercially available statistical program (GraphPad Prism 4.0, GraphPad Software, San
Diego, CA, USA). The unpaired t-test was used to compare the effects of pregnenolone
administration on rat serum neuroactive steroid levels. The paired t-test was used to compare
the effects of progesterone challenge on each neuroactive steroid in the human samples.
3. Results
3.1. Analytical method validation
Chromatography and mass spectrometry—The neuroactive steroids were identified
by monitoring specific ions at the corresponding retention time as shown in Table 1. The data
acquisition was broken into retention windows corresponding to the elution of the different
neuroactive steroid groups (Table 1). Total ion chromatograms after injection of 1000 pg/ml
of neuroactive steroid standards in human charcoal-stripped serum (Figure 2a) and after
injection of human serum under basal conditions (Figure 2b) show a good separation for the
steroids of interest. We also obtained clear separation of the four different isomers, 3α,5α-, 3α,
5β-, 3β,5α-and 3β,5β-THP (Figure 3), thus preventing any false estimates due to interference.
Calibration standard curves—Unknown amounts of each neuroactive steroid were
obtained by interpolating linear regression standard curves. The area ratio of mass to charge
(m/z) for each neuroactive steroid relative to the m/z of the respective deuterated internal
standard was plotted against the concentrations of neuroactive steroids (2, 10, 20, 50, 100, 200,
500, 1000, 2000 and 3000 pg/ml, Figure 4). Correlation coefficient values (r2) were between
0.995 and 0.999, as shown in Figure 4.
No detectable signal was observed for any of the neuroactive steroids in a blank injected after
the highest standard concentration (data not shown), demonstrating absence of carryover from
a high concentration sample to the next sample. Nonetheless, to control for possible carryover,
a blank was injected following every third sample.
Method validation—To validate the method and determine accuracy, sensitivity, extraction
efficiency and linearity, we spiked 300 μl of human charcoal-stripped serum with increasing
concentrations of neuroactive steroids. Linear regression plots of the theoretical vs. the actual
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value were obtained for each neuroactive steroid (Figure 5). Pearson correlations suggest that
the measured concentrations of neuroactive steroids are very close or identical to the spiked
amount, demonstrating good accuracy and linearity of the method and suggesting a good
estimation of recovery for each neuroactive steroid across the purification/derivatization
procedures. The pregnenolone assay was also validated (Linear regression: y = 1.051× - 21.62;
r2 = 0.9966; Pearson r = 0.9983; p<0.0001, figure not shown). Low concentrations of 3α,5α-
THP, 3α,5β-THP, 3α,5α-THDOC, 3α,5β-THDOC, 3α,5α-A, 3α,5β-A and pregnenolone were
detected in human charcoal-stripped serum and this resulted in overestimation of steroid levels
at concentrations between 10 and 100 pg/ml (Figure 5). In contrast, the 3α,5α- and 3α,5β-A-
diols exhibited absolute accuracy even at low concentrations, consistent with the lack of any
levels detected in human charcoal-stripped serum.
Precision and reproducibility of GC-MS—Intra-assay and inter-assay variability for
each steroid are shown in Table 2. For intra-assay variability, five replicates of quality control
samples (human charcoal-stripped serum spiked with 30, 300 and 3000 pg/ml) were assayed
along with the calibration standards in the same assay. Inter-assay variability was obtained by
comparing five different analytical runs of quality control samples (human charcoal-stripped
serum spiked with 30, 300 and 3000 pg/ml).
Limit of detection of GC-MS—Only peaks with a signal to noise ratio equal to or greater
than 5 were quantified. The lowest amount in the calibration standard curve that was accurately
and repeatedly detected was 2 pg/ml for 3α,5β-THP, 3α,5α-THDOC, 3α,5β-THDOC, 3α,5β-
A, 3α,5α-A-diol and 3α,5β-A-diol, and 10 pg/ml for 3α,5α-THP, 3α,5α-A and pregnenolone.
The limit of detection did not differ for quality control samples where undiluted stripped serum
(300 μl) was used as the matrix.
3.2. Biological application of the method
This GC-MS assay allows the simultaneous quantification of multiple neuroactive steroids. To
test its biological application, we investigated the effects of pharmacological challenge with
pregnenolone and progesterone, since these steroids have been used for treatment of human
disease. Pregnenolone (50 mg/kg, i.p.) was administered to male rats (Figure 6). Basal
neuroactive steroid levels (pg/ml ± SEM) in serum from male rats were: 225 ± 8.4 for 3α,5α-
THP, 92 ± 2.5 for 3α,5α-THDOC, 64 ± 5.4 for 3α,5α-A, 78 ± 14 for 3α,5β-A and 118 ± 25 for
3α,5α-A-diol. Basal 3α,5β-THP (145 ± 1.0) was detected only in 4/8 rats. 3α,5β-THDOC and
3α,5β-A-diol were undetectable. Administration of pregnenolone significantly increased levels
of 3α,5α-THP (+1488%, p<0.001), 3α,5α-THDOC (+205%, p<0.01), 3α,5α-A (+216%,
p<0.001) and 3α,5α-A-diol (+190%, p<0.01). In contrast, the increase in 3α,5β-THP (+569%)
was not statistically significant. 3α,5β-THDOC and 3α,5β-A-diol were also increased, from
undetectable levels to 271 ± 101 and to 2.4 ± 0.9 (pg ± SEM; 5/8), respectively, while 3α,5β-
A levels did not change. Basal pregnenolone levels were 293 ± 84 (pg ± SEM, data not shown);
they were dramatically increased (greater than 1000 fold) in all rats following pregnenolone
administration, but the precise measure of this increase was above the range of detection.
Next, we investigated the effects of pharmacological challenge with oral micronized
progesterone (300 mg) in 16 healthy women (Figure 7). Basal neuroactive steroid serum levels
(pg/ml ± SEM) during the follicular phase were: 249 ± 35 for 3α,5α-THP, 810 ± 458 for 3α,
5β-THP, 277 ± 82 for 3α,5α-A and 50 ± 17 for 3α,5β-A. 3α,5α-THDOC was detected in 6/16
subjects and basal levels were 50 ± 9.9; 3α,5β-THDOC was detected only in 3/16 subjects with
basal levels of 82 ± 9.2. As expected, administration of progesterone significantly increased
levels of 3α,5α-THP (+1806%, p<0.0001), 3α,5β-THP (+575%, p<0.001) and 3α,5α-THDOC
(+309%, p<0.001). 3α,5β-THDOC was also increased by 307%, however this increase did not
reach statistical significance, probably due to the small number of control subjects with
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detectable levels (3/16). Indeed, levels of 3α,5β-THDOC were detected in 13/16 subjects after
pharmacological challenge with progesterone. In contrast, administration of progesterone did
not alter 3α,5α-A and 3α,5β-A levels. Pregnenolone levels were also not altered by
progesterone challenge (806 ± 132 and 861 ± 113 pg/ml ± SEM for basal and after progesterone
challenge, respectively; data not shown). The testosterone metabolites 3α,5α-A-diol and 3α,
5β-A-diol were not measured in these subjects.
4. Discussion
We have described a highly selective and validated procedure for the simultaneous
measurement of GABAergic 3α,5α- and 3α,5β-reduced metabolites of progesterone,
deoxycorticosterone, DHEA and testosterone, as well as their precursor pregnenolone in serum.
Although several GC-MS methods are available for measurements of neuroactive steroids
[21,22,29,47-51] (see also Purdy et al.[52] for review), this is the first demonstration and
validation of procedures that allow the simultaneous measurement of eight GABAergic
neuroactive steroids and one precursor from the same sample. The method employs highly
sensitive negative chemical ionization GC-MS and allows the identification of different
isomers (both 5α- and 5β-reduced neuroactive steroids). The method has been validated using
spiked human charcoal-stripped serum samples and sample preparation and purification is
achieved with relatively high-throughput. This method allows a good separation of all these
neuroactive steroids, including all four isomers, 3α,5α-, 3α,5β-, 3β,5α- and 3β,5β-THP, thus
preventing any false estimates due to interference. The ability to measure all eight GABAergic
neuroactive steroids from the same 300 μl aliquot of serum is particularly useful when only
small volumes of sample can be obtained (frequently the case in clinical studies). The intra-
and inter-assay variability and sensitivity are similar to previous published work for 3α,5α-
THP[46,50], 3α,5β-THP[46], 3α,5α-A[47], 3α,5β-A[47], 3α,5α-A-diol[47], 3α,5β-A-diol[47]
and pregnenolone[46,47,50,51] in serum. No data is available for 3α,5α-THDOC and 3α,5β-
THDOC.
This assay can be used to measure neuroactive steroids in biological samples. This is important
especially because clinical trials using the neuroactive steroid precursors progesterone and
pregnenolone have appeared for traumatic brain injury, multiple sclerosis and schizophrenia
[35-37,41,42]. Indeed, it is not yet clear if the therapeutic effects in these trials are due to
progesterone or pregnenolone per se or to their neuroactive metabolites. Therefore, this
improved GC-MS-based method for neuroactive steroids measurement could be used to
evaluate the therapeutic role of these compounds. However, the clinical utility of this method
is yet to be established and further studies are needed.
The assay has several limitations including its high cost and labor intensive procedures. While
the sensitivity of the assay for 3α,5α-THP is comparable to some previous studies[46,50], other
authors have reported slightly better sensitivity using HPLC purification prior to GC-MS[29]
or better sensitivity to 3α,5α-THP, 3α,5α-A and 3α,5β-A using different GC-MS settings[47],
but direct comparisons of solid phase purification vs. HPLC purification or the different GC-
MS settings have yet to be performed and are needed to determine which approach offers more
sensitivity. The limit of detection is unlikely to limit the usefulness of the assay since
neuroactive steroid levels in the physiological range are reliably detected, but substantial
decreases in neuroactive steroid levels may not be quantifiable.
This assay has been validated for its use in serum samples. However, the same approach could
be used to measure cerebrospinal fluid levels of neuroactive steroids. There is very limited data
on neuroactive steroid levels in cerebrospinal fluid. Levels of 3α,5α-THP[22,45,58,59], and
pregnenolone[22,45,60,61] have been measured in human cerebrospinal fluid and are altered
in depression and post-traumatic stress disorder[22,59,60]. 3α,5α-A has also been found in
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human cerebrospinal fluid[45]. A direct comparison of cerebrospinal fluid and serum levels
has only been made for 3α,5α-THP, where levels were found to be the same in both biological
fluids and were similarly decreased in patients with Parkinson's disease[58]. Furthermore,
Naylor et al.,[61] showed that cerebrospinal fluid levels of both pregnenolone and DHEA are
correlated with brain levels, suggesting that changes in cerebrospinal fluid neuroactive steroids
levels are a good indication of changes in brain levels of these neuromodulators. These methods
may be useful to expand our knowledge of GABAergic neuroactive steroids in human
cerebrospinal fluid.
We tested the biological application of the assay in rats by measuring neuroactive steroid levels
following acute administration of pregnenolone. Basal levels of 3α,5β-THP, 3α,5β-THDOC,
3α,5β-A, and 3α,5β-A-diol were very low or undetectable in serum from control rats, as
expected, due to low 5β-reductase activity. This enzyme is expressed mainly in the liver and
its activity decreases in adult rats[62]. The administration of pregnenolone to male rats induced
a dramatic increase in the 3α,5α-reduced neuroactive steroids, with greater than ten-fold
increases in 3α,5α-THP and approximately three-fold increases in 3α,5α-THDOC, 3α,5α-A,
and 3α,5α-A-diol. These results suggest that pregnenolone selectively promotes the production
of progesterone and its 3α,5α-reduced metabolites in male rats, perhaps since the other steroids
require more biosynthetic steps for their production. It is possible that different ratios would
be found at later time points or in specific endocrine tissues such as adrenals, testicles or brain.
We tested the application of the assay in humans by measuring neuroactive steroid levels
following acute administration of progesterone. Basal 3α,5α- and 3α,5β-THDOC are not
particularly abundant in humans. Levels were less than 30 pg/ml in 10/16 and 13/16 healthy
women, respectively. Higher levels of 3α,5α-THDOC were measured in humans by
radioimmunoassay[63] (basal values 2 ng/ml) or by GC-MS[64] (basal values 67 pg/ml), likely
due to different technique or to lack of appropriate internal standards in those assays. Basal
levels of the DHEA metabolites 3α,5α-A and 3α,5β-A were similar to the progesterone
metabolites, however the level of 3α,5α-A was five fold higher than 3α,5β-A while 3α,5β-THP
was twice the level of 3α,5α-THP. The relative ratios of different steroids may have
undetermined physiological relevance. Progesterone administration elevated all four
GABAergic neuroactive steroids derived from progesterone and deoxycorticosterone, however
effects on 3α,5β-THDOC were not significant, probably since this steroid was undetectable
prior to progesterone administration in 13/16 subjects. There was no effect of progesterone on
the DHEA metabolites. Because progesterone increased both 3α,5α- and 3α,5β-THDOC levels
in healthy women, these neuroactive steroids may have biological relevance, particularly
during the luteal phase of the menstrual cycle, during pregnancy or after stimulation of the
hypothalamic-pituitary-adrenal axis[9,10,46,55,57,65,66]. In contrast to humans, 3α,5α-
THDOC is measurable in serum of male rats under control conditions. This could be attributed
to a different progesterone metabolism in humans vs. rodents.
Our results show that administration of pregnenolone or progesterone selectively alters
GABAergic neuroactive steroid levels. This would suggest that the therapeutic potential of
pregnenolone and progesterone could be attributable to their conversion into the GABAergic
neuroactive steroids. Indeed, the neuroactive steroid 3α,5α-THP is protective in animal models
of traumatic brain injury[43]. In addition, 3α,5α-THP levels are altered in both traumatic brain
injury[34] and schizophrenia[29], two of the disorders for which progesterone and
pregnenolone, respectively, have shown a therapeutic efficacy. However, the therapeutic
potential of neuroactive steroids may have even greater applicability since there is evidence of
dysregulation in several neurological and psychiatric diseases[5,16,22,28-30,67].
Furthermore, 3α,5α-THP has neuroprotective and neurotrophic effects[30-32], suggesting a
therapeutic potential for neurodegenerative diseases[33,68]. 3α,5α-THP reduces inflammatory
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cytokines after traumatic brain injury[69], suggesting a role for neuroactive steroids in the
inflammation process, a field that is relatively unexplored.
Furthermore, the relevance of the different 5α- vs. 5β-isomers of the GABAergic neuroactive
steroids is not well understood, likely due to the lack of a convenient method to measure them.
The 5β-isomers, 3α,5β-THP and 3α,5β-THDOC, are equipotent modulators of GABAA
receptors and may therefore be equally important in brain physiology. Some studies have
shown they are present in human serum and modulated by pregnancy, disease and treatment.
For example, 3α,5α-THP and 3α,5β-THP vary across pregnancy, but increases in 3α,5α-THP
were much greater[46,65]. A decrease in the ratio of the 5α/5β isomers of THP was observed
around parturition[70]. Depressed patients exhibit a decrease in peripheral 3α,5α-THP and
3α,5β-THP[44] and treatment with the antidepressant mirtazapine increased their
concentrations[71]. Concentrations of 3α,5α-THP and 3α,5β-THP were also decreased during
panic attacks[72]. Further studies are clearly needed to explore the role of both 5α- and 5β-
isomers of all GABAergic neuroactive steroids in health and disease.
Finally, the simultaneous measurement of the 3α,5α- and 3α,5β-reduced neuroactive steroids
can also be used to explore differential regulation of the biosynthetic pathways involved in the
conversion of progesterone, deoxycorticosterone, DHEA and testosterone and to explore
whether certain physiological or pathological states are associated with alterations in the
different metabolic pathways that lead to neuroactive steroids synthesis. While most prior
studies have focused on the progesterone metabolite 3α,5α-THP, the physiological significance
of the deoxycorticosterone, DHEA and testosterone GABAergic metabolites are largely
unknown. The simultaneous measurement of these neuroactive steroids is important not only
to further explore their physiological role, but also to identify biomarkers of disease risk,
treatment response and more selective therapeutic targets.
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Biosynthetic pathway for the GABAergic neuroactive steroids measured herein (indicated in
bold capitalized letters). Abbreviations 3α,5α-THP: (3α,5α)-3-hydroxypregnan-20-one; 3α,
5β-THP: (3α,5β)-3-hydroxypregnan-20-one; 3α,5α-THDOC: (3α,5α)-3,21-
dihydroxypregnan-20-one; 3α,5β-THDOC: (3α,5β)-3,21-dihydroxypregnan-20-one; 3α,5α-
A: (3α,5α)-3-hydroxyandrostan-17-one; 3α,5β-A: (3α,5β)-3-hydroxyandrostan-17-one; 3α,
5α-A-diol: (3α,5α,17β)-androstane-3,17-diol; 3α,5β-A-diol: (3α,5β,17β)-androstane-3,17-
diol; 5α-DHP: 5α-dihydroprogesterone; 5β-DHP: 5β-dihydroprogesterone; 5α-DHDOC: 5α-
dihydrodeoxycorticosterone; 5β-DHDOC: 5β-dihydrodeoxycorticosterone; 5α-DHT: 5α-
dihydrotestosterone; 5β-DHT: 5β-dihydrotestosterone; DHEA: dehydroepiandrosterone;
HSD: hydroxysteroid dehydrogenase.
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Total ion chromatograms of neuroactive steroids obtained in selected ion monitoring mode for
1000 pg/ml standard mixture in human charcoal-stripped serum (a) and human serum under
basal conditions (b). The data acquisition was broken into retention windows corresponding
to the elution of the different neuroactive steroid groups, as shown in Table 1. The target and
qualifier ions monitored for each neuroactive steroid are also shown in Table 1.
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Total ion chromatogram obtained in selected ion monitoring shows good separation of a 1000
pg/ml mixture of 3α,5α-, 3α,5β-, 3β,5α- and 3β,5β-THP isomers. For each isomer, the ions
474.4 and 494.4 were monitored (as indicated in Table 1).
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Calibration curves for each neuroactive steroid standard. Steroid amounts (0, 2, 10, 20, 50,
100, 200, 500, 1000, 2000 and 3000 pg/ml) were plotted versus area ratios of their respective
deuterium-labeled internal standards. The data is the average ± SEM of three to five
experiments for each neuroactive steroid.
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Analytical validation of the assay. Linear regression plots for each neuroactive steroid obtained
by spiking 300 μl of charcoal-stripped human serum with increasing concentrations of
neuroactive steroids (0, 10, 30, 50, 100, 300, 500 and 1000 pg/ml). Squares represent the actual
amount spiked and triangles represent the amount obtained after the entire experimental
procedure. The data is the average ± SEM of three to five experiments for each neuroactive
steroid.
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Effect of pregnenolone administration to male rats on neuroactive steroid serum levels.
Pregnenolone (50 mg/kg) or vehicle (45% β-cyclodextrine) was administered i.p. 60 minutes
before sacrifice. Levels are expressed as pg/ml and are average ± SEM of 8 subjects. In the
vehicle-treated group 3α,5β-THP was detected in 4/8 rats, while 3α,5β-THDOC and 3α,5β-A-
diol were undetectable (n.d.). *p<0.01 and **p<0.001 vs. the respective vehicle-treated control
values; unpaired t test.
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Progesterone challenge to healthy women selectively alters neuroactive steroid serum levels.
Blood samples were obtained 15 minutes before (basal) and 160 minutes after oral
administration of 300 mg of micronized progesterone. Levels are expressed as pg/ml and are
average ± SEM of 16 subjects. 3α,5α-THDOC was detected only in 6/16 subjects in the basal
group and 14/16 in the progesterone group. 3α,5β-THDOC was detected only in 3/16 subjects
in the basal group and 13/16 in the progesterone group. *p<0.001 and **p<0.0001 vs. the
respective basal values; paired t test.
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Table 1
Retention time, target ion and qualifier ion for each neuroactive steroid and deuterium labeled internal standard
(IS).
Neuroactive steroid Retention Time Target Ion m/z Qualifier Ion m/z
Group 1: 13.5-18 min
3α,5α-A-diol 14.69 664.4 684.4
3α,5β-A-diol 15.06 664.4 684.4
d4-3α,5α-A (IS) 15.42 470.4 450.4
3α,5α-A 15.47 466.4 446.4
3α,5β-A 15.85 446.4 466.4
Group 2: 18-21 min
d4-3α,5α-THP (IS) 19.09 497.4 477.4
3α,5α-THP 19.16 474.4 494.4
3α,5β-THP 19.47 474.4 494.4
Group 3: 21-23.5 min
d4-Pregnenolone (IS) 21.82 495.4 475.4
Pregnenolone 21.93 492.4 472.4
Group 4: 23.5-31 min
d3-3α,5α-THDOC (IS) 23.91 492.4 516.4
3α,5α-THDOC 24.07 490.4 513.4
3α,5β-THDOC 24.45 490.4 513.4
Neuroactive steroids were identified by monitoring the two most abundant ions (target ion and qualifier ion) at the corresponding retention time for
each compound. The data acquisition was broken into retention windows corresponding to the elution of the different neuroactive steroid groups.
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